Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 in renal cell carcinoma: Lessons from CheckMate 9ER and IMmotion 151
Restricted accessEditorialFirst published online March, 2021
Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 in renal cell carcinoma: Lessons from CheckMate 9ER and IMmotion 151
HannaKS.A review of checkpoint inhibitors in the management of renal cell carcinoma. J Oncol Pharm Pract2020;
26: 445–458.
2.
ChoueiriTKMotzerRJ.Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med2017;
376: 354–366.
3.
JammalNPanEHurwitzM, et al.
Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma – a retrospective study. J Oncol Pharm Pract2020;
26: 556–563.
4.
HanYLiuDLiL.PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res2020;
10: 727–742.
5.
LuJLee-GabelLNadeauMC, et al.
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract2015;
21: 451–467.
6.
ZhangYZhouHZhangL.Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?J Immunother Cancer2018;
6: 135.
7.
TartaroneARovielloGLeroseR, et al.
Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a Meta-analysis. Future Oncol2019;
15: 2423–2433.
8.
DuanJCuiLZhaoX, et al.
Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and Meta-analysis. JAMA Oncol2020;
6: 375–384.
9.
HuangGSunXLiuD, et al.
The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis. Oncotarget2018;
9: 4239–4248.
10.
RiniBIPlimackERStusV, et al.
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med2019;
380: 1116–1127.
11.
PlimackERRiniBIStusV, et al.
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): updated analysis of KEYNOTE-426. Jco2020;
38: 5001–5001.
12.
Choueiri TK, Motzer Rj, Rini BI, et al. Updated efficacy results from the JAVELIN renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 2020; 31: 1030–1039.
13.
McDermottDFHuseniMAAtkinsMB, et al.
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med2018;
24: 749–757.
14.
RozaliENHatoSVRobinsonBW, et al.
Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol2012;
2012: 656340–656348.
15.
TangYZhangPWangY, et al.
The biogenesis, biology, and clinical significance of exosomal PD-L1 in cancer. Front Immunol2020;
11: 604.
16.
DaassiDMahoneyKMFreemanGJ.The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol2020;
20: 209–215.
